Student Innovator Team ‘Enginuity’ Selected for Honorable Mention at the 2023 DEBUT Challenge
Team Enginuity was selected for their innovation’s ability to create a positive impact by addressing health and clinical challenges
Team Enginuity was selected for their innovation’s ability to create a positive impact by addressing health and clinical challenges
U-M’s student innovator team, Enginuity, was recently selected for an honorable mention at the 12th annual Design by Biomedical Undergraduate Teams (DEBUT) Challenge. Enginuity was selected for their innovation’s ability to create a positive impact by addressing health and clinical challenges.
Millions of people in the U.S. have neurogenic bladder disorder. Treated through clean intermittent catheterization (CIC), the process can be time-consuming and ineffective and result in complications like infections or kidney stones. Enginuity developed Fast-Cath, an accessible, portable device that drains and irrigates bladders while maintaining safe pressure, flow, and urine volume levels.
Congratulations to:
Team Captain: Jayanth Tatikonda
Team Members: Connie Gao, Benjamin Gerber, Ritika Pansare, Joel Pingel
Faculty Sponsor: Dr. Rachael Schmedlen
Enginuity will be recognized at the the Annual Meeting of the Biomedical Engineering Society in October 2023. The DEBUT Challenge is oriented toward undergraduate student teams working on innovative solutions for real-world problems in healthcare. Submissions were judged on the basis of the significance of the problem being addressed, the impact of the proposed solution on potential users and clinical care, the ingenuity of the design, and whether the solution had a working prototype.
The National Institute of Biomedical Imaging and Bioengineering (NBIB) and VentureWell have partnered to support the DEBUT Challenge, and together have awarded a total of $145,000 in prizes for 2023. The winners of the DEBUT Challenge will be honored at an award ceremony during the Annual Meeting of the Biomedical Engineering Society in October 2023.